$RYAN

Vulcan Value Partners is Bullish on Ryan Specialty Holdings (RYAN)

Vulcan Value Partners’ Q2 2026 investor letter highlighted Ryan Specialty Holdings (NYSE:RYAN). The firm cited 11.8% Q1 organic revenue growth but said Ryan cut its 2026 organic revenue outlook to mid-single-digit from high-single-digit. Vulcan noted robust E&S submission growth despite 25% to 35% property rate declines, plus a $300MM share repurchase authorization increase. RYAN closed at $44.09 on July 30, 2026.

Original reporting
Published Jul 31, 2026, 1:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 2:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vulcan Value Partners is Bullish on Ryan Specialty Holdings (RYAN) — source image
Decision brief

The 30-second read

$RYANNeutralLow
01

Why it matters

Ryan is described as having strong submission growth in E&S but facing premium growth pressure from property rate declines, leading to a reduced 2026 organic revenue outlook. The letter also notes an incremental $300MM share repurchase authorization after exhausting an initial authorization.

02

Market read

For traders, the most decision-relevant elements are the reported outlook cut to mid-single-digit organic revenue growth and the additional $300MM repurchase authorization, both affecting near-term valuation and sentiment.

03

What to watch

The piece does not quantify how much of the organic growth slowdown is mix, pricing, or underwriting changes, so traders may be underestimating earnings sensitivity to rate declines.

Relevance 4/10Novelty 3/10Timing: investor-letter commentary published today, no new filing or same-day catalyst described

Background

Vulcan Value Partners’ Q2 2026 investor letter discusses its long-term, lower-risk approach and spotlights Ryan Specialty as an undervalued holding.

Company-level read

Ticker impact

$RYANNeutralMedium confidence
Context

Vulcan Value Partners cites Ryan’s Q1 organic revenue growth of 11.8% but says Ryan cut its 2026 outlook to mid-single-digit growth.

Expected impact

Near-term sentiment may soften on the outlook cut, but support could come from the $300MM incremental repurchase authorization and continued submission strength.

Evidence & confidence

The article’s decision-relevant facts are the 2026 organic revenue outlook reduction and the incremental buyback authorization, both directly tied to Ryan’s fundamentals. However, it is framed as an investor-letter recap rather than a fresh company filing, limiting incremental impact versus what the market may already know.

Market effects

Highlights pressure from E&S property rate declines (25% to 35%) while volumes remain robust, a read-through for specialty insurance distribution underwriting economics.

Cites state-level divergence in E&S premiums and submissions (California, Florida, Texas) that may inform regional underwriting expectations.

Limited direct global spillover; mostly US E&S market dynamics and company-specific capital return.

Counterpoint

The guidance cut could signal more persistent rate pressure than management frames as short-term, making the buyback less of a fundamental offset.

Key entities

  • Vulcan Value Partners

    Author of the Q2 2026 investor letter that highlights Ryan Specialty’s fundamentals and capital return.

  • Ryan Specialty Holdings, Inc.

    Specialty insurance services firm discussed as a portfolio contributor, with guidance and buyback details cited.

Related articles

$RYANMedAI 8/10

Ryan Specialty posts Q2 revenue gain as E&S market slows

Ryan Specialty Holdings, Inc. reported second-quarter 2026 net commissions and fees of $902.7 million, up 7.4% year-over-year. Total revenue for the quarter reached $916.6 million, a 7.2% increase from $855.2 million a year earlier. Organic revenue growth came in at 6.7%, down from 7.1% in the prior-year period. The deceleration continues a trend across multiple quarters as the broader E&S market moderates.

$RYANMed

RYAN SPECIALTY HOLDINGS, INC. (RYAN): Results of Operations and Financial Condition

RYAN SPECIALTY HOLDINGS, INC. (RYAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 RYAN SPECIALTY REPORTS SECOND QUARTER 2026 RESULTS - Total Revenue grew 7.2% year-over-year to $916.6 million - - Organic Revenue Growth Rate* of 6.7% year-over-year - - Net Income of $108.4 million , or $0.33 per diluted share - - Adjusted EBITDAC* grew 6.0% year-over-year to

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.